Timothy W. Synold

8.1k citations

194 papers · 5.9k indexed · 1 hit paper · h-index 39

Impact in

Oncology top 1%
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology
Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism

Papers in

Oncology 97
- Cancer Treatment and Pharmacology 35
- Colorectal Cancer Treatments and Studies 16
- Drug Transport and Resistance Mechanisms 10
- Cancer Immunotherapy and Biomarkers 10
Hematology 27
- Acute Myeloid Leukemia Research 10

Co-authors: Barry M. Forman Isabelle Dussault James H. Doroshow Jana Portnow Bixin Xi Mary V. Relling Behnam Badie Jeff Longmate
Journals: Journal of Clinical Oncology (42 papers)Cancer Chemotherapy and Pharmacology (24 papers)Clinical Cancer Research (9 papers)Blood (7 papers)Cancer Research (5 papers)
Partner nations: United States Canada Netherlands

In The Last Decade

Timothy W. Synold

186 papers receiving 5.8k citations

Hit Papers

align trajectories log scale

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux 2001 · 682 citations

Peers

Countries citing papers authored by Timothy W. Synold

Since Specialization

Citations

This map shows the geographic impact of Timothy W. Synold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy W. Synold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy W. Synold more than expected).

Fields of papers citing papers by Timothy W. Synold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy W. Synold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy W. Synold. The network helps show where Timothy W. Synold may publish in the future.

Co-authors

The 25 scholars most cited alongside Timothy W. Synold, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Timothy W. Synold Line = papers co-authored together Timothy W. Synold links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors Cancer Chemotherapy and Pharmacology ·Miriam Palmiero, Timothy W. Synold, Behnam Badie, An Liu, Tanja Krunić, Julie Kilpatrick, Suzette Blanchard, Jana Portnow	2024	0
2	Abstract 1831: Reduction of PMN-MDSC level/activity following the consumption of white button mushroom in prostate cancer murine models and patients: A translational study to mitigate cancer progression Cancer Research ·Xiaoqiang Wang, Shoubao Ma, Przemyslaw Twardowski, Clayton Lau, Manuel Lamúa, 紀平深見, Jinhui Wang, Xiwei Wu, Paul Frankel, Timothy G. Wilson, Timothy W. Synold, Cary A. Presant, Jianhua Yu, Shiuan Chen	2024	1
3	A phase 1 trial of 8‐chloro‐adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics Cancer ·Vinod Pullarkat, Lisa S. Chen, Joycelynne Palmer, Jianying Zhang, Timothy W. Synold, Ralf Buettner, Le Xuan Truong Nguyen, Guido Marcucci, Ni‐Chun Tsai, Vorsrilg Roland, Maftuhatus Sholihah, Varsha Gandhi, Steven T. Rosen	2023	2
4	Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study Journal of Clinical Oncology ·Jingran Ji, Can‐Lan Sun, Harvey Jay Cohen, Timothy W. Synold, Hyman B. Muss, Mina S. Sedrak	2022	16
5	Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design SHILAP Revista de lepidopterología ·Mustafa Raoof, Kevin M. Sullivan, Paul Frankel, Marwan Fakih, Timothy W. Synold, Dean Lim, Yanghee Woo, I. Benjamin Paz, Yuman Fong, Rebecca Thomas, Sue Chang, Melissa Eng, Anosh Aslam Khan, Richard L. Whelan, Danielle K. DePeralta, Marc A. Reymond, Jeremy Jones, Amit Merchea, Thanh H. Dellinger	2022	6
6	Multiple Treatment Cycles of Neural Stem Cell Delivered Oncolytic Adenovirus for the Treatment of Glioblastoma Cancers ·正上林, Anthony Castelletto, Mustafa Kocatepe, H.K. Goon, 이영식, Laureen Beaugeard, Mohamed Hammad, Margarita Gutova, Jana Portnow, Timothy W. Synold, David T. Curiel, Maciej S. Lesniak, Karen S. Aboody, Rachael Mooney	2021	7
7	863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort Annals of Oncology ·Mihaela Cristea, Paul Frankel, Timothy W. Synold, David B. Stewart, Hussein Ali Amine, Alain C. Jung, Sharon P. Wilczynski, H. Wang, Gottfried E. Konecny, Melissa Eng, Kavya R, Yi–Ju Chen, О.В. Рябоконь, DEXTER BROWN, Thanh H. Dellinger, Amy Hakim, S H Liyanage, Richard J. Morgan, Virginia H. Ean, Mark T. Wakabayashi	2020	1
8	Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients Cancer Gene Therapy ·Jana Portnow, Behnam Badie, M. Suzette Blanchard, Julie Kilpatrick, Revathiswari Tirughana, Marianne Z. Metz, Shu Mi, Орозали Кубанычбек уулу, Julie A. Ressler, Massimo D’Apuzzo, Karen S. Aboody, Timothy W. Synold	2020	15
9	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma Clinical Cancer Research ·Robert Chen, Alex F. Herrera, Yang Haitao, Lu Chen, Jun Wu, 多喜夫岡田, Timothy W. Synold, Vu N. Ngo, Sandrine Puverel, Matthew Mei, Leslie Popplewell, Shuhua Yi, Joo Y. Song, Shu Tao, Xiwei Wu, Wing C. Chan, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Edward M. Newman	2019	61
10	A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity Cancer Chemotherapy and Pharmacology ·Mihaela Cristea, Paul Frankel, Timothy W. Synold, Saul E. Rivkin, Dean Lim, Vincent Chung, Joseph Chao, Mark T. Wakabayashi, Benjamin Paz, Ernest Han, Paul Lin, Lucille Leong, Amy Hakim, Mary Carroll, Neal Prakash, Thanh H. Dellinger, Min Park, Robert J. Morgan	2019	25
11	The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA Clinical Cancer Research ·Long Gu, Robert Lingeman, Yasheng Bu, Emily Sun, Qi Cui, Jianfei Chao, Weidong Hu, Hongzhi Li, Robert J. Hickey, Jeremy M. Stark, Yate‐Ching Yuan, Yuan Chen, Steven Vonderfecht, Timothy W. Synold, Yanhong Shi, Karen L. Reckamp, David Horne, Linda H. Malkas	2018	33
12	Leflunomide Inhibits c-Myc Signaling and Impairs Myeloma Cell Growth Blood ·Ralf Buettner, L.F. Martin, Enrico Caserta, Domenico Viola, Joycelynne Palmer, Xiwei Wu, Nagarajan Vaidehi, Hongzhi Li, Timothy W. Synold, Amrita Krishnan, Flavia Pichiorri, Michael Rosenzweig, Steven T. Rosen	2017	2
13	Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial Blood ·Michael Rosenzweig, Joycelynne Palmer, Ni‐Chun Tsai, Ralf Buettner, Noah Walton, Myo Htut, Chatchada Karanes, Nitya Nathwani, Flavia Pichiorri, Firoozeh Sahebi, George Somlo, Timothy W. Synold, Xiwei Wu, Amrita Krishnan, Stephen J. Forman, Steven T. Rosen	2017	0
14	Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients Clinical Cancer Research ·Jana Portnow, Timothy W. Synold, Behnam Badie, Revathiswari Tirughana, Simon F. Lacey, Massimo D’Apuzzo, Marianne Z. Metz, Joseph Najbauer, Victoria Bedell, Tien Vo, Margarita Gutova, Paul Frankel, Mike Y. Chen, Karen S. Aboody	2016	127
15	Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors British Journal of Cancer ·Sadegh Mansoubi, Paul Frankel, Timothy W. Synold, S. A. MOHAMMMED, Joanne Mortimer, Anthony B. El-Khoueiry, David R. Gandara, Mihaela Cristea, Vincent Chung, Dean Lim, Karen L. Reckamp, Dennis H. Lau, L. Austin Doyle, Christopher Ruel, S. Subha, Edward M. Newman	2014	14
16	A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance Cancer Research ·Bingsen Zhou, Leila Su, Shuya Hu, Weidong Hu, M.L. Richard Yip, Jun Wu, Shikha Gaur, D. Lynne Smith, Yate‐Ching Yuan, Timothy W. Synold, David Horne, Yun Yen	2013	65
17	Nelfinavir Induces Liposarcoma Apoptosis through Inhibition of Regulated Intramembrane Proteolysis of SREBP-1 and ATF6 Clinical Cancer Research ·Min Guan, Kristen Fousek, Chunling Jiang, M.H Polymeropoulous, Timothy W. Synold, Bixin Xi, Chu-Chih Shih, Warren Chow	2011	67
18	Translation of grape seed extract as a natural aromatase inhibitor for breast cancer prevention. Cancer Epidemiology and Prevention Biomarkers ·Melanie R. Palomares, Sheryl Phung, Elizabeth T. Eng, Фридман Михаил, DaweiXING, Timothy W. Synold, Shiuan Chen	2006	1
19	Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. PubMed ·Eric Masson, Timothy W. Synold, Mary V. Relling, John D. Schuetz, J T Sandlund, Ching‐Hon Pui, Evans We	1996	16
20	Renal Function and Methotrexate Clearance in Children With Newly Diagnosed Leukemia Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Daryl J. Murry, Timothy W. Synold, Ching‐Hon Pui, John H. Rodman	1995	18

About Timothy W. Synold

Timothy W. Synold is a scholar working on Oncology, Hematology, Genetics, Cancer Research and Pulmonary and Respiratory Medicine, having authored 194 papers that have together received 5.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (35 papers), Cancer therapeutics and mechanisms (23 papers), Glioma Diagnosis and Treatment (16 papers), Cancer Genomics and Diagnostics (16 papers), Colorectal Cancer Treatments and Studies (16 papers), Acute Myeloid Leukemia Research (10 papers), Drug Transport and Resistance Mechanisms (10 papers) and Cancer Immunotherapy and Biomarkers (10 papers). The work is most often cited by research in Oncology (2.3k citations), Pharmacology (582 citations), Genetics (560 citations), Hematology (521 citations) and Molecular Biology (2.4k citations). Timothy W. Synold has collaborated with scholars based in United States, Canada and Netherlands. Frequent co-authors include Barry M. Forman, Isabelle Dussault, James H. Doroshow, Jana Portnow, Bixin Xi, Mary V. Relling, Behnam Badie, Jeff Longmate, Paul Frankel and Kim Margolin. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Clinical Cancer Research, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact